Publications

Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection.

Liu C. et al, (2024), Nature communications, 15

The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86.

Zhou D. et al, (2024), Nature communications, 15

Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.

Michael BD. et al, (2023), Nature communications, 14

Quantifying neutralising antibody responses against SARS-CoV-2 in dried blood spots (DBS) and paired sera

Roper KJ. et al, (2023), Scientific Reports, 13

Structural comparison of typical and atypical E2 pestivirus glycoproteins.

Aitkenhead H. et al, (2023), Structure (London, England : 1993)

COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance.

Bou-Antoun S. et al, (2023), The Journal of antimicrobial chemotherapy, 78, ii37 - ii42

Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study.

Bešević J. et al, (2023), Journal of epidemiology and community health

Experimental phasing opportunities for macromolecular crystallography at very long wavelengths.

El Omari K. et al, (2023), Commun Chem, 6

ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.

Ni T. et al, (2023), iScience, 26

Structure of Bovine CD46 Ectodomain

Aitkenhead H. et al, (2023), Viruses, 15, 1424 - 1424

Accelerating drug target inhibitor discovery with a deep generative foundation model.

Chenthamarakshan V. et al, (2023), Science advances, 9

Broadly neutralizing antibodies against COVID-19.

Zhou D. et al, (2023), Current opinion in virology, 61

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.

Ragonnet-Cronin M. et al, (2023), Nature communications, 14

Cryogenic electron ptychographic single particle analysis with wide bandwidth information transfer

Pei X. et al, (2023), Nature Communications, 14

ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface

Zhang P. et al, (2023)

Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK

Wei J. et al, (2023), Nature Communications, 14

Investigation of the milling characteristics of different focused-ion-beam sources assessed by three-dimensional electron diffraction from crystal lamellae.

Parkhurst JM. et al, (2023), IUCrJ

Characterization of the rotavirus assembly pathway in situ using cryoelectron tomography

Shah PNM. et al, (2023), Cell Host & Microbe, 31, 604 - 615.e4

Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses

Dijokaite-Guraliuc A. et al, (2023), Cell Reports, 42, 112271 - 112271

Isolation of a pair of potent broadly neutralizing mAb binding to RBD and SD1 domains of SARS-CoV-2

Stuart D. et al, (2023)

Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.

Siggins MK. et al, (2023), Immunology, 168, 473 - 492

The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.

Goldswain H. et al, (2023), Genome biology, 24

Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region

Emmenegger M. et al, (2023), iScience, 26, 105928 - 105928

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75

Huo J. et al, (2023), Cell Reports, 42, 111903 - 111903

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

Liew F. et al, (2023), eBioMedicine, 87, 104402 - 104402

Publisher Correction: A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation.

Bahar MW. et al, (2022), Commun Biol, 5

A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation.

Bahar MW. et al, (2022), Commun Biol, 5

Switching of Receptor Binding Poses between Closely Related Enteroviruses

Zhou D. et al, (2022), Viruses, 14, 2625 - 2625

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6.

Dijokaite-Guraliuc A. et al, (2022), Cell discovery, 8

Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum.

Huo J. et al, (2022), Cell discovery, 8

Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study.

Vink E. et al, (2022), Open forum infectious diseases, 9

Production and Characterisation of Stabilised PV-3 Virus-like Particles Using Pichia pastoris.

Sherry L. et al, (2022), Viruses, 14

Nonlytic cellular release of hepatitis A virus requires dual capsid recruitment of the ESCRT-associated Bro1 domain proteins HD-PTP and ALIX.

Shirasaki T. et al, (2022), PLoS pathogens, 18

Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom

Vihta1 KD. et al, (2022), Clinical Infectious Diseases

Delineating organizational principles of the endogenous L-A virus by cryo-EM and computational analysis of native cell extracts

Schmidt L. et al, (2022)

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

Tuekprakhon A. et al, (2022), Cell, 185, 2422 - 2433.e13

SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection

Wei J. et al, (2022), Nature Communications, 13

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

Nutalai R. et al, (2022), Cell, 185, 2116 - 2131.e18

Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol

Knight SR. et al, (2022), Thorax, 77, 606 - 615

Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum

Tuekprakhon A. et al, (2022)

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Wei J. et al, (2022), Nature Medicine, 28, 1072 - 1082

An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status

Lumley SF. et al, (2022), Clinical Infectious Diseases, 74, 1208 - 1219

Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study.

Närhi F. et al, (2022), The Lancet. Digital health, 4, e220 - e234

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Wei J. et al, (2022), Nature Medicine

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Dejnirattisai W. et al, (2022), Cell, 185, 467 - 484.e15

Purification of African Swine Fever Virus.

Shimmon GL. et al, (2022), Methods in molecular biology (Clifton, N.J.), 2503, 179 - 186

Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2

Huang K-YA. et al, (2022), Theranostics, 12, 1 - 17

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.

Dejnirattisai W. et al, (2021), Lancet (London, England)

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Dejnirattisai W. et al, (2021)

Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective.

Halawa S. et al, (2021), Nature reviews. Cardiology

Cookies on this website

Publications